Send to

Choose Destination
Oncotarget. 2015 Apr 20;6(11):8579-92.

Prognostic and predictive values of long non-coding RNA LINC00472 in breast cancer.

Author information

Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
Department of Surgical Sciences, Azienda Ospedaliero-Universitaria, Turin, Italy.
Department of Surgical Sciences, University of Turin, Torino, Italy.
Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut, USA.
Cancer Biology Program, University of Hawaii Cancer Center, Honolulu, Hawaii, USA.


LINC00472 is a novel long intergenic non-coding RNA. We evaluated LINC00472 expression in breast tumor samples using RT-qPCR, performed a meta-analysis of over 20 microarray datasets from the Gene Expression Omnibus (GEO) database, and investigated the effect of LINC00472 expression on cell proliferation and migration in breast cancer cells transfected with a LINC00472-expressing vector. Our qPCR results showed that high LINC00472 expression was associated with less aggressive breast tumors and more favorable disease outcomes. Patients with high expression of LINC00472 had significantly reduced risk of relapse and death compared to those with low expression. Patients with high LINC00472 expression also had better responses to adjuvant chemo- or hormonal therapy than did patients with low expression. Results of meta-analysis on multiple studies from the GEO database were in agreement with the findings of our study. High LINC00472 was also associated with favorable molecular subtypes, Luminal A or normal-like tumors. Cell culture experiments showed that up-regulation of LINC00472 expression could suppress breast cancer cell proliferation and migration. Collectively, our clinical and in vitro studies suggest that LINC00472 is a tumor suppressor in breast cancer. Evaluating this long non-coding RNA in breast tumors may have prognostic and predictive value in the clinical management of breast cancer.


LINC00472; breast; lincRNA

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center